Royalty Pharma (STU:RPD) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


STU:RPD Royalty Pharma PLC STU:RPD
72 GF Score
Price €48.03
GF Value €32.95
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Royalty Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

STU:RPD vs BNTX, INSM, ROIV: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Royalty Pharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Royalty Pharma Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Margin of Safety % (DCF FCF Based) falls into.


STU:RPD
72GF Score
Royalty Pharma PLC STU:RPD
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Royalty Pharma (STU:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €48.03 is trading 45.8% above its estimated GF Value™ of €32.95. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for STU:RPD:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €32.95 vs. price of €48.03 (45.8% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the STU:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for STU:RPD

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.03
Price
€32.95
GF Value